Rigel Pharmaceuticals Inc (RIGL) News

Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update

Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business...

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO...

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1...

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer PR Newswire SOUTH...

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and...

Form 8-K - Current report

Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®

Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO® PR Newswire SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]